Weiying Zhou
Chongqing, 400016, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Corrigendum to "Activation of PERK/eIF2α/ATF4 signaling inhibits ERα expression in breast cancer" [Neoplasia 65 (2025) 101165].
Journal: Neoplasia (New York, N.Y.)
Published: July 08, 2026
Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence.
Journal: Journal of medicinal chemistry
Published: March 10, 2026
CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to inhibit oxidative stress and ferroptosis.
Journal: Free radical biology & medicine
Published: October 17, 2025
Dual AMPK activation and TXNIP suppression underlie the superior anti-diabetic action of rosiglitazone-metformin co-crystal (RZM): evidence from preclinical models.
Journal: Journal of drug targeting
Published: July 14, 2025
Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan.
Journal: Clinical and translational science
Published: February 24, 2025
Mechanisms underlying seizures and hypothermia during busulphan administration.
Journal: Bone marrow transplantation
Published: December 25, 2024
Evaluation of anti-diabetic effects of glimepiride/metformin cocrystal.
Journal: Journal of drug targeting
Published: November 01, 2024
Activation of PERK/eIF2α/ATF4 signaling inhibits ERα expression in breast cancer.
Journal: Neoplasia (New York, N.Y.)
Published: August 30, 2024
SGK3 promotes estrogen receptor-positive breast cancer proliferation by activating STAT3/ZMIZ2 pathway to stabilise β-catenin.
Journal: British journal of pharmacology
Published: May 17, 2024
Cost-effectiveness analysis of trilaciclib for preventing myelosuppression in small cell lung cancer patients treated with etoposide, carboplatin, and atezolizumab.
Journal: American journal of cancer research
Published: March 20, 2024
INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib.
Journal: Biochemical pharmacology
Published: December 25, 2023
TCF12-regulated GRB7 facilitates the HER2+ breast cancer progression by activating Notch1 signaling pathway.
Journal: Journal of translational medicine
Published: November 28, 2023
Last Updated: 09/26/2026